ARPINO, GRAZIA

ARPINO, GRAZIA  

DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 162 (tempo di esecuzione: 0.042 secondi).
Titolo Tipologia Data di pubblicazione Autore(i) File
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 1.1 Articolo in rivista 2005 Arpino, Grazia; Weiss, H; Lee, Av; Schiff, R; DE PLACIDO, Sabino; Osborne, Ck; Elledge, R. M.
Potent inhibition of EGFR(ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu Over-expressing breast tumor xenografts. 4.1 Articoli in Atti di convegno 2006 M. F., Rimawi; H. L., Weiss; Arpino, Grazia; G. S., Morris; R. D., Soliz; R. M., Ward; T. M., Gilmer; C. K., Osborne; R., Schiff
Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. 4.1 Articoli in Atti di convegno 2004 Arpino, Grazia; Weiss, H; Wakeling, Ae; Osborne, K; Schiff, R.
GMO-Gestione Malattie Oncologiche in Regione Campania. 2.1 Contributo in volume (Capitolo o Saggio) 2011 Arpino, Grazia; Cammarota, Simona; DE ANGELIS, Carmine; Pizzi, Claudia; Perone, Vincenzo; Tommasielli, Giuseppina; Arpino, Giovanni; Novellino, Ettore; DE PLACIDO, Sabino
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 1.1 Articolo in rivista 2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, C; Ciardiello, F; Tortora, Giampaolo; D'Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, Rossella; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
Health-care costs associated with breast cancer management 1.5 Abstract in rivista 2010 Cammarota, S.; Citarella, A.; Menditto, Enrica; Putignano, D.; Riegler, S.; De Luca, L.; Malorni, L.; DE PLACIDO, Sabino; Arpino, Grazia
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 1.1 Articolo in rivista 2005 DE LAURENTIIS, Michelino; Arpino, Grazia; Massarelli, E; Ruggiero, A; Carlomagno, Chiara; Ciardiello, F; Tortora, G; D’Agostino, D; Caputo, F; Cancello, G; Montagna, E; Malorni, L; Zinno, L; Lauria, R; Bianco, Ar; DE PLACIDO, Sabino
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 4.1 Articoli in Atti di convegno 2001 Francesco, Cognetti; Arpino, Grazia; DE LAURENTIIS, Michelino; Paola, Papaldo; Chiara, Sguotti; Modesto, D'Aprile; Francesco, Recchia; DE PLACIDO, Sabino; Angelo Raffaele, Bianco
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. 1.1 Articolo in rivista 2003 Valerie Jeanne, Bardou; Arpino, Grazia; Richard M., Elledge; C., Kent Osborne; Gary M., Clark
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. 1.1 Articolo in rivista 2004 Arpino, Grazia; Valerie J., Bardou; Gary M., Clark; Richard M., Elledge
Premalignant and in situ breast disease: biology and clinical implications. 1.1 Articolo in rivista 2005 Arpino, Grazia; Rodolfo, Laucirica; Richard M., Elledge
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. 1.1 Articolo in rivista 2005 Arpino, Grazia; D. R., Ciocca; H., Weiss; D. C., Allred; P., Daguerre; L., Vargas Roig; M., Leuzzi; F., Gago; R., Elledge; S. K., Mohsin
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. 1.1 Articolo in rivista 2005 Arpino, Grazia; H. L., Weiss; G. M., Clark; S. G., Hilsenbeck; C. K., Osborne
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. 1.1 Articolo in rivista 2008 Arpino, Grazia; Lisa, Wiechmann; C., Kent Osborne; Rachel, Schiff
Idoxifene vs. Tamoxifen: A Randomized Comparison in Postmenopausal Patients with Metastatic Breast Cancer 4.1 Articoli in Atti di convegno 2002 Arpino, Grazia; Nair Krishnan, M; Doval Dinesh, C; V. J., Bardou; G., Clark; R., Elledge
The hormone receptor status of a contralateral breast cancer is independent of the first primary in patients not receiving adjuvant systemic therapy. 4.1 Articoli in Atti di convegno 2003 Arpino, Grazia; H., Weiss; S., Hilsenbeck; K., Osborne
Clinical and biologic features of ER- PR- HER-2- breast cancer compared to estrogen or HER-2 driven phenotypes 4.1 Articoli in Atti di convegno 2005 Arpino, Grazia; H., Weiss; R., Elledge
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). 4.1 Articoli in Atti di convegno 2012 M. F., Rimawi; C. J., Poole; J. M., Ferrero; J. R., De la Haba Rodriguez; L., Mitchell; C. H., Pelizon; Arpino, Grazia
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 4.1 Articoli in Atti di convegno 2012 Arpino, Grazia; Pensabene, Matilde; Forestieri, Valeria; Condello, Caterina; Maria Anna Sarno, ; Ruocco, Raffaella; Cerillo, Ivana; DE ANGELIS, Carmine; Lauria, Rossella; Crispo, Anna; DE PLACIDO, Sabino
Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) on core needle biopsy (CNB) — Clinical significance 4.1 Articoli in Atti di convegno 2003 Arpino, Grazia; C., Allred; S., Mohsin; H., Weiss; D., Conrow; R., Elledge